BTI earnings call for the period ending June 5, 2020.
News & Analysis: British American Tobacco
Tobacco vaccine production is a surprisingly economical endeavor, saving time and costs. Kentucky Bioprocessing, the biotechnology subsidiary of British American Tobacco, is leading the way.
A host of issues has made the tobacco company's shares look inexpensive.
Their biotech units are in the race to find a vaccine.
The U.S. International Trade Commission has announced a probe into Altria and Philip Morris for alleged patent violations over iQOS heat-not-burn technology.
The science behind plant-based vaccines, including those developed using tobacco plants, could offer the opportunity for quickly developed therapies.
This won't be the first time these companies have fought in court over intellectual property related to e-cigarettes.
There are several good reasons consumers would be motivated to change their habits.
The DOJ and Treasury Department are examining a potential violation of sanctions against an unnamed country.
A shifting product focus and hefty dividend are motivating investors.